All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ketamine analogs
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Small molecule
Partner/Sponsor/Collaborator: CYBIN
Deal Size: $15.7 million Upfront Cash: Undisclosed
Deal Type: Acquisition December 07, 2020
Details:
Adelia’s leadership team brings deep clinical and commercialization experience, including past commercial success in psychedelics through the development of proprietary ketamine analogs as well as strong understanding of the underlying science.